CSI Market
Sign In | Register

Elicio Therapeutics Inc (ELTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ELTX quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Elicio Therapeutics Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-39.57
Depreciation & amortization0.20
Amortization of Other Assets0.22
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation2.70
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants1.92
Operating Lease Right Of Use Asset Amortization Expense0.92
Fair Value Option Changes In Fair Value Gain Loss-
Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss-
Increase Decrease In Grant Receivables-
Increase Decrease In Operating Lease Liability-0.90
Non Cash Placement Agent Fee-
Notes Receivable Fair Value Adjustment-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Gain Loss On Issuance Of Warrants-
Costs Expensed Upon The Issuance Of Warrants-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.37
Increase (Decrease) in Accrued Liabilities-1.99
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.15
Other Working Capital-0.17
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.06
Discontinued operations0.00
Net Cash flow from Operating Activities-36.95
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired in Excess of Payments to Acquire Business0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.02
Financing Activities
Short-term debt Net9.87
Other borrowing transactions0.00
Long-term debt - borrowings9.14
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock17.69
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-19.49
Payments For Broker Warrant Exercises-
Payments For Forward Stock Split Fractional Shares-
Proceeds From Financing Obligation-
Finance Lease Principal Payments-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents19.49
Payment Of Warrant Issuance Costs-
Proceeds From Issuance Of Common Stock Warrants From July Public Offering-
Proceeds From Issuance Of Common Stock From At The Market Offerings Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities36.70
Effect of exchange rate on cash flow0.05
Discontinued operations0.00
Free Cash Flow-36.97
Total Cash Flow-0.23
4 historic quarters locked

Sign in to unlock the full Elicio Therapeutics Inc cash flow history.

Sign In Create Free Account

About Elicio Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001601485-26-000027

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License